Ryvu Therapeutics SA - Asset Resilience Ratio

Latest as of March 2026: 16.62%

Ryvu Therapeutics SA (RVU) has an Asset Resilience Ratio of 16.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Ryvu Therapeutics SA's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

zł33.40 Million

≈ $9.19 Million USD Cash + Short-term Investments

Total Assets

zł200.96 Million

≈ $55.31 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Ryvu Therapeutics SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Ryvu Therapeutics SA balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Ryvu Therapeutics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore RVU long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	zł0.00	0%
Short-term Investments	zł33.40 Million	16.62%
Total Liquid Assets	zł33.40 Million	16.62%

Asset Resilience Insights

Good Liquidity Position: Ryvu Therapeutics SA maintains a healthy 16.62% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Ryvu Therapeutics SA Industry Peers by Asset Resilience Ratio

Compare Ryvu Therapeutics SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Ryvu Therapeutics SA (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Ryvu Therapeutics SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	21.42%	zł48.07 Million ≈ $13.23 Million	zł224.44 Million ≈ $61.77 Million	+4.03pp
2024-12-31	17.39%	zł65.86 Million ≈ $18.12 Million	zł378.78 Million ≈ $104.24 Million	-26.20pp
2023-12-31	43.58%	zł175.73 Million ≈ $48.36 Million	zł403.20 Million ≈ $110.97 Million	+43.47pp
2022-12-31	0.11%	zł528.00K ≈ $145.31K	zł474.98 Million ≈ $130.72 Million	-2.07pp
2021-12-31	2.18%	zł4.99 Million ≈ $1.37 Million	zł228.81 Million ≈ $62.97 Million	-6.26pp
2020-12-31	8.45%	zł24.97 Million ≈ $6.87 Million	zł295.64 Million ≈ $81.36 Million	+8.52pp
2018-12-31	-0.08%	zł-196.04K ≈ $-53.95K	zł255.70 Million ≈ $70.37 Million	+0.11pp
2017-12-31	-0.19%	zł-196.04K ≈ $-53.95K	zł103.57 Million ≈ $28.50 Million	-0.64pp
2014-12-31	0.45%	zł120.00K ≈ $33.03K	zł26.80 Million ≈ $7.38 Million	-0.22pp
2013-12-31	0.67%	zł120.00K ≈ $33.03K	zł17.98 Million ≈ $4.95 Million	+1.72pp
2012-12-31	-1.06%	zł-162.04K ≈ $-44.60K	zł15.35 Million ≈ $4.22 Million	-0.50pp
2011-12-31	-0.56%	zł-98.08K ≈ $-26.99K	zł17.50 Million ≈ $4.82 Million	--

pp = percentage points

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$106.26 Million

zł386.11 Million PLN

Market Cap Rank

#19053 Global

#147 in Poland

Share Price

zł16.70

Change (1 day)

-1.65%

52-Week Range

zł13.76 - zł29.90

All Time High

zł75.00